Stomach Paralysis and Mounjaro: Separating Fact from Concern

You're feeling full for hours and wondering if something is wrong

Imagine finishing a small lunch and still feeling uncomfortably full at dinner time. That sensation is familiar to many people in the first weeks on Mounjaro, and it is, by design, part of what the medicine does. Tirzepatide activates both GIP and GLP-1 receptors, and one of the downstream effects is a measurable slowing of how quickly food moves from the stomach into the small intestine. The NHS medicines page for tirzepatide describes this as part of the drug's normal action: it reduces appetite partly by prolonging the feeling of satiety after eating.

This is meaningfully different from gastroparesis as a pathological condition. True gastroparesis involves nerve or muscle damage that prevents the stomach from emptying at all, causing persistent vomiting, weight loss from inability to eat, and a range of complications. The slowing effect of Mounjaro is pharmacological, dose-related, and in most people entirely manageable. Understanding that distinction matters, it changes whether what you are experiencing is an expected adjustment or a signal to call your GP.

If you want a broader picture of what tirzepatide is and how it works, the tirzepatide overview on this site covers the mechanism in plain language.

What the evidence says about gastroparesis as a risk with GLP-1 and dual-agonist medicines

The concern about gastroparesis gained traction after a 2023 study in the journal JAMA (published before tirzepatide's widespread use) reported an association between GLP-1 receptor agonists and an increased risk of gastroparesis diagnosis in people using these medicines for weight management. That study was observational, meaning it identified an association rather than proving causation, and the absolute risk remained small. The picture for tirzepatide specifically is less settled because it is a newer medicine carrying the MHRA's Black Triangle (▼) status, which triggers enhanced post-marketing surveillance precisely so that signals like this can be monitored in real-world populations.

At present, gastroparesis is not listed in the Mounjaro UK Summary of Product Characteristics as a known adverse effect. The SURMOUNT clinical programme, which involved thousands of adults across its trials, did not identify gastroparesis as a treatment-emergent event at rates that reached the threshold for inclusion in the label. That does not mean risk is zero, it means the evidence to date does not support it as an established risk at the population level. The MHRA continues to review post-marketing data, and the Yellow Card scheme at yellowcard.mhra.gov.uk is how patients and clinicians contribute to that ongoing safety picture.

For context on the gastrointestinal side effects that are listed and what to expect from them, the guide to stomach symptoms on Mounjaro is worth reading alongside this page.

When stomach symptoms on Mounjaro need medical attention

Most GI symptoms (nausea, loose stools, indigestion, that stretched-stomach feeling) are strongest in the first one to four weeks after starting or after each dose increase, and they settle for the majority of people as their body adjusts. Keeping your pen in the fridge door and injecting on the same evening each week gives your routine a rhythm that makes it easier to track whether symptoms are improving or escalating.

There are patterns that warrant a call to your GP or prescriber rather than waiting it out. Vomiting that is frequent enough to prevent you keeping food or fluids down, abdominal pain that is severe, worsening or radiates to your back, or symptoms that show no sign of easing after several weeks, these are not normal adjustment responses. The MHRA's January 2026 Drug Safety Update specifically flagged acute pancreatitis as an infrequent but serious risk with GLP-1 medicines; the key symptom is severe, persistent stomach pain that may spread to the back, sometimes with vomiting. That is not gastroparesis, but it is a reason to seek urgent help without delay.

If you are experiencing stomach pain at a level that concerns you, the Mounjaro stomach pain page sets out the specific signs that need same-day medical attention. For broader questions about stomach symptoms and what is within the expected range, the stomach pains and Mounjaro resource addresses the most common scenarios. And if your symptoms relate specifically to a particular dose, our stomach ache after Mounjaro page looks at timing and dose patterns in more detail.

Deciding whether Mounjaro is appropriate given these concerns

If you have a pre-existing history of gastroparesis, delayed gastric emptying, or significant gastrointestinal conditions, this is material that a prescriber needs to know before any decision is made. The licensed eligibility criteria for Mounjaro cover adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition, but BMI alone is never the whole picture. A prescriber assesses your full medical history, your current medicines, and any conditions that might make Mounjaro unsuitable or require extra monitoring.

The same applies if you are considering Mounjaro alongside other treatments, or if you have already been taking it and developed symptoms that concern you. If cost is part of the calculation, the Mounjaro cost context page explains what legitimate private treatment includes and what to be cautious about when prices look unusually low. A fuller picture of the treatment landscape, including how to explore weight management options that suit your situation, is available through the treatment overview.

Mounjaro is a clinically significant medicine with a strong evidence base. It is also one where your individual circumstances shape everything, from starting dose to how symptoms are managed over time. A free consultation with our prescribers is the right place to work through questions like these, based on your actual health picture rather than a generic article.